Impact of Treatment Patterns and Sequencing on Clinical and Economic Outcomes in Patients with Metastatic Urothelial Cancer: IMPACT UC II Study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.In metastatic urothelial cancer, first-line immuno-oncology monotherapy showed higher mortality and costs compared to platinum-based chemotherapy. Real-world data reveal significant differences in outcomes and resource utilization.
Area Of Science
- Uro-oncology
- Real-world evidence
- Health economics
Background
- The IMPACT UC II study evaluated real-world outcomes in metastatic urothelial cancer (mUC) patients.
- Data were collected before the US approval of first-line avelumab maintenance therapy.
Purpose Of The Study
- To assess overall survival (OS), progression, healthcare resource utilization (HCRU), and costs in mUC patients.
- To compare outcomes across different first-line treatment strategies.
Main Methods
- Retrospective analysis of adult mUC patient claims data (July 2015-June 2020).
- Three first-line cohorts: cisplatin-based chemotherapy, carboplatin-based chemotherapy, and immuno-oncology (IO) monotherapy.
- OS, 1L-to-2L progression, HCRU, and costs were analyzed.
Main Results
- Compared to cisplatin, IO monotherapy doubled mortality risk; carboplatin increased it by 1.5 times.
- First-line to second-line progression was highest with carboplatin (74.4/100 person-years) vs. cisplatin (51.9) and IO (29.8).
- IO monotherapy incurred the highest median and cumulative 24-month costs for mUC-related care.
Conclusions
- First-line immuno-oncology monotherapy was associated with increased mortality, HCRU, and costs versus platinum-based chemotherapy.
- Approximately one-third of mUC patients received first-line therapy in this cohort.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...